ORION OYJ
STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE
Composition of the
The Board of Directors of
Annika Ekman Petteri Karttunen Minna Maasilta Veli-Matti Mattila - Hilpi Rautelin
Seppo Salonen
Hilpi Rautelin was appointed as Chair of the Committee.
The Committee prepares and presents a recommendation to the Board of Directors for the proposal to the Annual General Meeting concerning the composition of the Board.
The essentials of the charter of the Nomination Committee and a description of the appointment process of its members are provided at https://www.orion.fi/en/investors/corporate-governance/board-of-directors/nomination-committee/charter-of-the-nomination-committee/ , a page in the Corporate Governance section of the Orion Group website.
President and CEO | SVP, Corporate Functions |
Contact person:
tel. +358 10 426 3054
Publisher:
Communications
Orionintie 1A, FI-02200
http://www.orion.fi/en
http://www.twitter.com/OrionCorpIR
Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. Orion's net sales in 2023 amounted to
© OMX, source
